Sevoflurane
In clinical developmentAlso known as Petrem, SevoFlo, Sevospire, Sojourn+7 more
Petrem, SevoFlo, Sevospire, Sojourn, Ultane, Sevofluran, Sevoflurano, Sévoflurane, 1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane, Fluoromethyl 2,2,2-trifluoro-1-(trifluromethyl)ethyl ether, Sevofluranum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Effect of Sevoflurane on Sweat Threshold in Children of Different Ages
Dynamic Effects of Different Anesthetic Agents on the Immune Function of Healthy Volunteers
Sevoflurane's Effect on Neurocognition Study
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes5
Journals, researchers & institutions
- Journal of advanced research1
- Cao Q1
- Chen Y1
- Dong H1
- Jia S1
- Liu H1
- Liu Y1
- Ou Z1
- Su B1
- Binzhou Medical University Hospital1
- Histology and Embryology & K.K. Leung Brain Research Centre1
- State Key Laboratory of Cellular Stress Biology1
- Xijing Hospital1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials